Lantern rouge of the SBF 120, Nanobiotix share falls below its 22.38 € support level

A share declining 3.82% and approaching its support level at 22.38 €

Nanobiotix share retreats 3.82% to 21.68 € during the session, while the SBF 120 loses 0.33%. The share is last in the index, followed by Société Générale which declines 2.90%. Over a week, the loss reaches 21.45%, and the decline rises to 35.28% over one month. The price is now below the support level at 22.38 €, a reference tested last week, while the RSI at 24 reflects an oversold configuration.

The three moving averages are above the price: the gap reaches 23.98% with the MA20 and 32.46% with the MA50. Net declared short positions reach 1.33% of capital, distributed between two funds, according to the declarations consulted. This level has progressed by 1.33 points in 30 days, but remains modest: it signals investors positioned downward, without in itself translating massive distrust.

Cash reserves of 110.9 M€ financing operations through 2029

This decline occurs despite a solid balance sheet. During the publication of the first half of 2026, on September 24, Nanobiotix reported 110.9 M€ in cash, compared to 52.8 M€ at the end of December 2025, following a capital increase of approximately 86 M€ in May. This amount is expected to finance operations through 2029, according to the company's statement. The share also maintains a gain of 17.06% over one year, but the recent sequence has significantly eroded this achievement.

The value is listed both in Paris (NANO) and on Nasdaq (NBTXR3 is developed with Johnson & Johnson). Both lines represent the same security: the Paris line is eligible for the PEA, not the American ADS. The support level at 22.38 € remains the level to watch in the coming sessions.